Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL
AP News,
The study brings together Verismo’s proprietary SynKIR™ platform and novel CD19 binder to treat CAR-naïve and post-CAR relapsed…
The study brings together Verismo’s proprietary SynKIR™ platform and novel CD19 binder to treat CAR-naïve and post-CAR relapsed…
Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL PR Newswire…
The study brings together Verismo's proprietary SynKIR™ platform and novel CD19 binder to treat CAR-naïve and post-CAR relapsed…
The study brings together Verismo's proprietary SynKIR™ platform and novel CD19 binder to treat CAR-naïve and post-CAR relapsed…